Menu
MapConnectionsTopicsBulgariaThe Night (K-TRIO)Marie Skłodowska-CurieFor studentsFor teachersMethodologySurprise me
HEDoctoral network2024–2027

eRaDicate · Innovative ligands for nuclear receptors to eradicate cancer relapse.

Horizon Europe — Marie Skłodowska-Curie Actions

Duration
2024-01-01 → 2027-12-31
EU contribution
€2,526,934
Participants
23
Scheme
HORIZON-TMA-MSCA-DN

Lines connect the coordinator with its partners.

Results in brief

Innovative ligands for nuclear receptors to eradicate cancer relapse.

The Marie-Skłodowska Curie Doctoral Network: “Innovative Ligands for Nuclear Receptors to Eradicate Cancer Relapse”, (eRaDicate) combines training and research for 11 doctoral candidates (DCs). Leading researchers and all DCs are part of this group that delivers secondments, schools, and eRaDicate training events. The research is at the Medical University of Vienna (MUV), University of Wroclaw (UWr), Medical University of Warsaw (MUW), University of Warsaw (UoW), University of Santiago de Compostela (USC), University of Birmingham (UOB), Ben-Gurion University of the Negev (BGU), and Trinity College Dublin (TCD)) and the one industrial partner TissueGnostics GmbH (TG)). The objectives are to 1) understand the roles of nuclear receptors retinoic acid receptor (RAR) and vitamin D receptor (VDR) in cancer; 2) design and synthesise highly innovative compounds that target these receptors for use to treat cancer stem cell-driven relapse and metastasis; and 3) devise pre-formulation strategies to the new compounds.

Data: CORDIS, © European Union

Project objective

The aim of the “eRaDicate” international, multidisciplinary, and intersectoral cancer drug research and development programme is to empower 10 young scientists to become specialists in cancer research and drug development, while developing new therapies against cancer stem cell-driven relapse and metastasis. Nuclear receptors, such as retinoic acid receptor (RAR) and vitamin D receptor (VDR), play key roles in many hallmarks of cancer and constitute effective targets for modern cancer therapy. To address the EU priority “Mission Cancer”, we will 1) test the anti-cancer activity of RAR and VDR targeting compounds; 2) design and synthesise a highly innovative dual action hybrid compound acting simultaneously as RARγ antagonist and VDR agonist; 3) devise pre-formulation strategies for our compounds; 4) and develop a novel, deep learning-based cancer analysis and diagnostics method. We will test how our RAR and VDR-targeting compounds affect stemness and metastatic potential in leukaemia, breast, prostate, colorectal, and ovarian cancer. In parallel, we will assess if the pan-RAR antagonist is effective against chemotherapy-induced neutropenia. For the development of the RAR and VDR targeting compounds into administrable medicines, ready for eventual commercialisation, we will develop pre-formulation strategies. We will generate a novel and highly innovative label-free image analysis method based on histoplasmonic cytometry. The project will have lasting scientific, economic, and societal impact.In order to be prepared for a wide spectrum of career opportunities, we will train the doctoral candidates (DCs) not only to perform original and independent research on an internationally competitive level, but also endow them with creative, critical and entrepreneurial mindset, coupled with persistence in following their objectives. Our consortium consists of 8 academic and 1 industrial beneficiary, as well as 12 associated partners to provide training and secondments.

Original text from CORDIS.

Participants

  • MEDIZINISCHE UNIVERSITAET WIEN · WienCoordinatorAustria
  • BEN-GURION UNIVERSITY OF THE NEGEV · Beer ShevaIsrael
  • BIOLUTION GMBH · WienAustria
  • DANUBE PRIVATE UNIVERSITY GMBH · KREMS-STEINAustria
  • ENVIGO RMS BV · HORSTNetherlands
  • Janssen Sciences Ireland UC · CorkIreland
  • KARL LANDSTEINER PRIVATUNIVERSITAT FUR GESUNDHEITSWISSENSCHAFTEN GMBH · Krems an der DonauAustria
  • LA TROBE UNIVERSITY · La Trobe UniversityAustralia
  • Mag. Franz TettingerAustria
  • PHYSIOLUTION GMBH · GreifswaldGermany
  • Pikralida sp. z o.o. · PoznańPoland
  • QUEENSLAND UNIVERSITY OF TECHNOLOGY - QLD QUT · BrisbaneAustralia
  • SHAARE ZEDEK MEDICAL CENTER · JerusalemIsrael
  • Selvita S.A. · KrakowPoland
  • THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO · TorontoCanada
  • THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN · DublinIreland
  • THE UNIVERSITY OF BIRMINGHAM · BirminghamUnited Kingdom
  • TISSUEGNOSTICS GMBH · WienAustria
  • UNIVERSIDAD DE SANTIAGO DE COMPOSTELA · Santiago De CompostelaSpain
  • UNIWERSYTET WARSZAWSKI · WarszawaPoland
  • UNIWERSYTET WROCLAWSKI · WroclawPoland
  • WARSZAWSKI UNIWERSYTET MEDYCZNY · WarszawaPoland
  • Wannaboo S.r.l. · ValdagnoItaly

Links

Data: CORDIS, © European Union